nach oben

Erschienen in:

01.06.2013 | Original article

¹²⁵I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region

verfasst von: M.-W. Huang, PhD, L. Zheng, PhD, S.-M. Liu, PhD, Y. Shi, PhD, J. Zhang, PhD, G.-Y. Yu, PhD, Prof. Dr. J.-G. Zhang, B.S.Med

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

This retrospective study was to evaluate the local control and survival of ¹²⁵I brachytherapy for recurrent and/or locally advanced adenoid cystic carcinoma (ACC) of the oral and maxillofacial region.

Patients and methods

A total of 38 patients with recurrent and/or locally advanced ACC of the oral and maxillofacial region received ¹²⁵I brachytherapy alone from 2001–2010. Twenty-nine were recurrent cases following previous surgery and radiation therapy. The other 9 cases involved primary tumors. Overall, 12 tumors were located in the major salivary glands, 12 in the minor salivary glands, and 14 in the paranasal region, the nasal cavity or the skull base. The prescribed dose was 100–160 Gy.

Results

Patients were followed for 12–122 months (median 51 months). The 2-, 5-, and 10-year local tumor control rates were 86.3, 59, and 31.5 %, respectively. The 2-, 5-, and 10-year overall survival rates were 92.1, 65 and 34.1 %, respectively. Tumors > 6 cm had significantly lower local control and survival rates. No severe complications were observed during follow-up.

Conclusion

¹²⁵I brachytherapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent ACC.

Ashamalla H, Rafla S, Zaki B et al (2002) Radioactive gold grain implants in recurrent and locally advanced head-and-neck cancers. Brachytherapy 1:161–166PubMedCrossRef

Avery CM, Moody AB, McKinna FE et al (2000) Combined treatment of adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg 29:277–279PubMedCrossRef

Ayukawa F, Shibuya H, Yoshimura R et al (2007) Curative brachytherapy for recurrent/residual tongue cancer. Strahlenther Onkol 183:133–137PubMedCrossRef

Balamucki CJ, Amdur RJ, Werning JW et al (2012) Adenoid cystic carcinoma of the head and neck. Am J Otolaryngol 33:510–518PubMedCrossRef

Bianchi B, Copelli C, Cocchi R et al (2008) Adenoid cystic carcinoma of intraoral minor salivary glands. Oral Oncol 44:1026–1031PubMedCrossRef

Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159PubMedCrossRef

Cowie VJ, Pointon RCS (1984) Adenoid cystic carcinoma of the salivary glands. Clin Radiol 35:331–333PubMedCrossRef

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef

Douglas JG, Laramore GE, Austin-Seymour M et al (2000) Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46:551–557PubMedCrossRef

10.

Emami B, Marks JE (1983) Re-irradiation of recurrent carcinoma of the head and neck by afterloading interstitial ¹⁹²Ir implant. Laryngoscope 93:1345–1347PubMed

11.

Glaser MG, Leslie MD, Coles I, Cheesman AD (1995) Iodine seeds in the treatment of slowly proliferating tumours in the head and neck region. Clin Oncol 7:106–109CrossRef

12.

Goldner G, Pötter R, Battermann JJ et al (2012) Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol 188:305–310PubMedCrossRef

13.

Grabenbauer GG, Rödel C, Brunner T et al (2001) Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol 177:338–344PubMedCrossRef

14.

Haddad A, Enepekides DJ, Manolidis S, Black M (1995) Adenoid cystic carcinoma of the head and neck: a clinicopathologic study of 37 cases. J Otolaryngol 24:201–205PubMed

15.

Harrison LB, Armstrong JG, Spiro RH et al (1990) Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 45:52–55PubMedCrossRef

16.

Iseli TA, Karnell LH, Graham SM et al (2009) Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol 123:1137–1144PubMedCrossRef

17.

Jiang YL, Meng N, Wang JJ et al (2010) CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers. Radiat Oncol 5:68PubMedCrossRef

18.

Julow J, Viola A, Major T et al (2004) Iodine-125 brachytherapy of brain stem tumors. Strahlenther Onkol 180:449–454PubMedCrossRef

19.

Khan AJ, DiGiovanna MP, Ross DA et al (2001) Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96:149–158PubMedCrossRef

20.

Kim KH, Sung MW, Chung PS et al (1994) Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 120:721–726PubMedCrossRef

21.

Kim GE, Park HC, Keum KC et al (1999) Adenoid cystic carcinoma of the maxillary antrum. Am J Otolaryngol 20:77–84PubMedCrossRef

22.

Ko YH, Lee MA, Hong YS et al (2007) Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin Oncol 37:805–811PubMedCrossRef

23.

Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE (2004) Adenoid cystic carcinoma of the head and neck—a 20 years experience. Int J Oral Maxillofac Surg 33:25–31PubMedCrossRef

24.

Konno A, Ishikawa K, Numata T et al (1998) Analysis of factors affecting long-term treatment results of adenoid cystic carcinoma of the nose and paranasal sinuses. Acta Otolaryngol Suppl 537:67–74PubMed

25.

Laurie SA, Ho AL, Fury MG et al (2011) Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12:815–824PubMedCrossRef

26.

Le QT, Birdwell S, Terris DJ et al (1999) Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 52:165–171PubMedCrossRef

27.

Leafstedt SW, Gaeta JF, Sako K et al (1971) Adenoid cystic carcinoma of major and minor salivary glands. Am J Surg 122:756–762PubMedCrossRef

28.

Li Q, Xu T, Gao JM et al (2011) Surgery alone provides long-term survival rates comparable to those of surgery plus postoperative for patients with adenoid cystic carcinoma of the palate. Oral Oncol 47:170–173PubMedCrossRef

29.

Lopes MA, Santos GC, Kowalski LP (1998) Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinoma. Head Neck 20:699–706PubMedCrossRef

30.

Mendenhall WM, Morris CG, Amdur RJ et al (2004) Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 26:154–162PubMedCrossRef

31.

Miglianico L, Eschwege F, Marandas P, Wibault P (1987) Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 13:673–678PubMedCrossRef

32.

Mücke T, Tannapfel A, Kesting MR et al (2010) Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx 37:615–620PubMedCrossRef

33.

Pandey M, Thomas S, Mathew A, Nair MK (2003) Malignant tumours of the minor salivary glands: a survival analysis of 17 years from a tertiary referral cancer centre. J Postgrad Med 49:25–58PubMedCrossRef

34.

Park RI, Liberman FZ, Lee DJ et al (1991) Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cancer of the head and neck. Laryngoscope 101:405–410PubMedCrossRef

35.

Peters N, Wieners G, Pech M et al (2008) CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 184:296–301PubMedCrossRef

36.

Prokopakis EP, Snyderman CH, Hanna EY et al (1999) Risk factors for local recurrence of adenoid cystic carcinoma: the role of postoperative radiation therapy. Am J Otolaryngol 20:281–286PubMedCrossRef

37.

Puthawala A, Nisar Syed AM, Gamie S et al (2001) Interstitial low-dose rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys 51:354–362PubMedCrossRef

38.

Rapidis AD, Givalos N, Gakiopoulou H et al (2005) Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 41:328–335PubMedCrossRef

39.

Renehan A, Gleave EN, Hancock BD et al (1996) Long-term follow-up of over 1000 patients with salivary gland tumors treated in a single centre. Br J Surg 83:1750–1754PubMedCrossRef

40.

Rhee CS, Won TB, Lee CH et al (2006) Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope 116:982–986PubMedCrossRef

41.

Richter J, Baier K, Flentje M (2008) Comparison of ⁶⁰cobalt and ¹⁹²iridium sources in high dose rate afterloading brachytherapy. Strahlenther Onkol 184:187–192PubMedCrossRef

42.

Ruge MI, Kocher M, Maarouf M et al (2011) Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 187:7–14PubMedCrossRef

43.

Russell JD, Bleach NR, Glaser M, Cheesman AD (1993) Brachytherapy for recurrent nasopharyngeal and nasoethmoidal tumours. J Laryngol Otol 107:115–120PubMedCrossRef

44.

Stannard C, Maree G, Munro R et al (2011) Iodine-125 orbital brachytherapy with a prosthetic implant in situ. Strahlenther Onkol 187:322–327PubMedCrossRef

45.

Stannard CE, Hering E, Hough J et al (2004) Post-operative treatment of malignant salivary gland tumors of the palate with iodine-125 brachytherapy. Radiother Oncol 73:307–311PubMedCrossRef

46.

Strnad V (2004) Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 180:710–717PubMedCrossRef

47.

Umeda M, Nishimatsu N, Yokoo S et al (2000) The role of radiotherapy for patients with adenoid cystic carcinoma of the salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:724–729PubMedCrossRef

48.

Vattemi E, Graiff C, Sava T et al (2008) Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther 8:393–402PubMedCrossRef

49.

Vikram B, Hilaris B (1984) Transnasal permanent interstitial implantation for carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 10:153–155PubMedCrossRef

50.

Wiseman SM, Popat SR, Rigual NR et al (2002) Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J 81:510–514, 516–517PubMed

51.

Zhang J, Zhang JG, Song TL et al (2008) ¹²⁵I seed implant brachytherapy-assisted surgery with preservation of facial nerve for treatment of malignant parotid gland tumors. Int J Oral Maxillofac Surg 37:515–520PubMedCrossRef

Titel: 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region
verfasst von: M.-W. Huang, PhD
L. Zheng, PhD
S.-M. Liu, PhD
Y. Shi, PhD
J. Zhang, PhD
G.-Y. Yu, PhD
Prof. Dr. J.-G. Zhang, B.S.Med
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 6/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0324-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

¹²⁵I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Simultane Radiochemotherapie mit 5-FU/Mitomycin bleibt bei Behandlung von Analkanalkarzinomen der bevorzugte Standard

Mitteilungen der Fachgesellschaften

The German evidence-based guidelines for Hodgkin’s lymphoma

Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre

Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy

Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie